SNB on hold, while becoming less keen on FX intervention
Highlights: The Swiss National Bank (SNB) kept interest rates unchanged, standing apart from global peers who have either already delivered hikes or signalled likely moves ahead. We reiterate our expectation that inflation will not durably rise beyond the 1 per cent level (midpoint of the 0 per cent - 2 per cent target) before 2028, which would delay a gradual normalisation of interest rate policy until then. While the market is currently pricing in as many as two hikes by June next year, we continue to expect the SNB’s first rate increase to be delivered in mid-2028. While we have a neutral view on USDCHF, we have recently also neutralised our view on EURCHF as the market digests the possibility of high rates for longer in Europe. While we remain neutral for Swiss equities, we have recently upgraded our SMI target for 2027, implying range trade performance until year end but double-digit returns next year, supported by earnings growth. We have also recently upgraded our view on European healthcare, including Swiss pharma. Large pharmaceutical companies face significant patent expirations over the coming years, increasing the need to acquire, partner with, or license innovative biotechnology assets. Switzerland’s healthcare sector benefits from the presence of several globally leading pharma companies, where positive developments are becoming evident.
- While geopolitical risks remain a concern, the SNB’s revised average forecasts for inflation are 0.7 per cent in 2026 (from 0.6 per cent) and 0.8 per cent in 2027 and 2028 (from 0.7 per cent). Meanwhile, economic growth forecasts were revised higher, driven by a stronger than expected GDP print in Q2 and the expectation that this momentum has carried into the current quarter
- The key takeaway of the meeting was on the Swiss Franc, whereby the Central Bank omitted a previously used sentence of “increased willingness” to intervene while dropping its directional bias towards countering currency strength
- In reaction to the meeting, CHF edged lower vs both EUR and USD, while the curve steepened, with 10-year rates climbing 4bps. Healthcare stocks led on the day thanks to their defensive qualities, while the overall index edged slightly lower in line with weaker global sentiment